Bristol-Myers Squibb Company entered into a definitive agreement to acquire Orbital Therapeutics, Inc. for $1.5 billion on October 10, 2025. Under the terms of the agreement, BMS will pay $1.5...

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further strengthens BMS’s industry-leading cell therapy portfolio, expanding CAR T-cell access to more patients in the future Bristol Myers Squibb (NYSE: BMY, “BMS”) and Orbital Therapeutics (“Orbital”) today announced a definitive agreement under which BMS will acquire Orbital, a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo , enabling treatments that provide the precision, control, and flexibility needed to address the underlying biology and unique complexities of each disease. “ In vivo CAR T represents a novel treatment approach that could redefine how we treat autoimmune diseases,” said Robert Plenge, MD, PhD, executive vice president, Chief Research Officer, BMS. “This acquisition enhances our robust cell therapy